<DOC>
	<DOCNO>NCT00009737</DOCNO>
	<brief_summary>This 2 arm study compare safety efficacy oral Xeloda , 5-fluorouracil combination leucovorin , patient undergo surgery colon cancer . Patients randomize receive either Xeloda 1250mg/m2 po bid day 1-14 every 21 day , leucovorin 20mg/m2 iv + 5-fluorouracil 425mg/m2 iv daily day 1 day 5 every 28 day . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Compared With 5-Fluorouracil Combination With Low-Dose Leucovorin Patients Who Have Undergone Surgery Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>adult patient 1875 year age ; histologically confirm colon cancer potentially curative resection tumor within 8 week study initiation . previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>